Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 212

1.

Global governance of antimicrobial resistance.

Rochford C, Sridhar D, Woods N, Saleh Z, Hartenstein L, Ahlawat H, Whiting E, Dybul M, Cars O, Goosby E, Cassels A, Velasquez G, Hoffman S, Baris E, Wadsworth J, Gyansa-Lutterodt M, Davies S.

Lancet. 2018 May 19;391(10134):1976-1978. doi: 10.1016/S0140-6736(18)31117-6. Epub 2018 May 17. No abstract available. Erratum in: Lancet. 2018 May 26;391(10135):2106.

PMID:
29864011
2.

Reply to Prim et al., "Is Colistin Susceptibility Testing Finally on the Right Track?"

Karvanen M, Malmberg C, Lagerbäck P, Friberg LE, Cars O.

Antimicrob Agents Chemother. 2018 Mar 27;62(4). pii: e02507-17. doi: 10.1128/AAC.02507-17. Print 2018 Apr. No abstract available.

3.

Unavailability of old antibiotics threatens effective treatment for common bacterial infections.

Tängdén T, Pulcini C, Aagaard H, Balasegaram M, Hara GL, Nathwani D, Sharland M, Theuretzbacher U, Cars O.

Lancet Infect Dis. 2018 Mar;18(3):242-244. doi: 10.1016/S1473-3099(18)30075-6. No abstract available. Erratum in: Lancet Infect Dis. 2018 Feb 28;:.

PMID:
29485082
4.

Lessons learnt during 20 years of the Swedish strategic programme against antibiotic resistance.

Mölstad S, Löfmark S, Carlin K, Erntell M, Aspevall O, Blad L, Hanberger H, Hedin K, Hellman J, Norman C, Skoog G, Stålsby-Lundborg C, Tegmark Wisell K, Åhrén C, Cars O.

Bull World Health Organ. 2017 Nov 1;95(11):764-773. doi: 10.2471/BLT.16.184374. Epub 2017 Oct 3.

5.

Predicting mutant selection in competition experiments with ciprofloxacin-exposed Escherichia coli.

Khan DD, Lagerbäck P, Malmberg C, Kristoffersson AN, Wistrand-Yuen E, Sha C, Cars O, Andersson DI, Hughes D, Nielsen EI, Friberg LE.

Int J Antimicrob Agents. 2018 Mar;51(3):399-406. doi: 10.1016/j.ijantimicag.2017.10.019. Epub 2017 Nov 7.

PMID:
29127049
6.

Colistin Is Extensively Lost during Standard In Vitro Experimental Conditions.

Karvanen M, Malmberg C, Lagerbäck P, Friberg LE, Cars O.

Antimicrob Agents Chemother. 2017 Oct 24;61(11). pii: e00857-17. doi: 10.1128/AAC.00857-17. Print 2017 Nov.

7.

Building bridges to operationalise one health - A Sino-Swedish collaboration to tackle antibiotic resistance.

Cars O, Xiao Y, Stålsby Lundborg C, Nilsson LE, Shen J, Sun Q, Bi Z, Börjesson S, Greko C, Wang Y, Liu Y, Ottoson J, Li X, Nilsson M, Yin H, Bi Z, Zheng B, Xia X, Chen B, Ding L, Sun P, Dyar OJ, Hulth A, Tomson G.

One Health. 2016 Sep 17;2:139-143. doi: 10.1016/j.onehlt.2016.09.002. eCollection 2016 Dec.

8.

Ensuring universal access to old antibiotics: a critical but neglected priority.

Pulcini C, Beovic B, Béraud G, Carlet J, Cars O, Howard P, Levy-Hara G, Li G, Nathwani D, Roblot F, Sharland M.

Clin Microbiol Infect. 2017 Sep;23(9):590-592. doi: 10.1016/j.cmi.2017.04.026. Epub 2017 May 15. No abstract available.

9.

Erratum to 'Forgotten antibiotics: a follow-up inventory study in Europe, the USA, Canada and Australia': [International Journal of Antimicrobial Agents 49/1 (2017) 98-101].

Pulcini C, Mohrs S, Beovic B, Gyssens I, Theuretzbacher U, Cars O; ESCMID Study Group for Antibiotic Policies (ESGAP); ReAct Working Group on Old Antibiotics.

Int J Antimicrob Agents. 2017 Apr;49(4):482. doi: 10.1016/j.ijantimicag.2017.02.006. Epub 2017 Mar 3. No abstract available.

PMID:
28264779
10.

Assessment of early combination effects of colistin and meropenem against Pseudomonas aeruginosa and Acinetobacter baumannii in dynamic time-kill experiments.

Tängdén T, Karvanen M, Friberg LE, Odenholt I, Cars O.

Infect Dis (Lond). 2017 Jul;49(7):521-527. doi: 10.1080/23744235.2017.1296183. Epub 2017 Mar 6.

PMID:
28264618
11.

A Novel Microfluidic Assay for Rapid Phenotypic Antibiotic Susceptibility Testing of Bacteria Detected in Clinical Blood Cultures.

Malmberg C, Yuen P, Spaak J, Cars O, Tängdén T, Lagerbäck P.

PLoS One. 2016 Dec 14;11(12):e0167356. doi: 10.1371/journal.pone.0167356. eCollection 2016.

12.

Forgotten antibiotics: a follow-up inventory study in Europe, the USA, Canada and Australia.

Pulcini C, Mohrs S, Beovic B, Gyssens I, Theuretzbacher U, Cars O; ESCMID Study Group for Antibiotic Policies (ESGAP), ReAct Working Group on Old Antibiotics.

Int J Antimicrob Agents. 2017 Jan;49(1):98-101. doi: 10.1016/j.ijantimicag.2016.09.029. Epub 2016 Nov 16. Erratum in: Int J Antimicrob Agents. 2017 Apr;49(4):482.

PMID:
27887966
13.

Evaluation of automated time-lapse microscopy for assessment of in vitro activity of antibiotics.

Ungphakorn W, Malmberg C, Lagerbäck P, Cars O, Nielsen EI, Tängdén T.

J Microbiol Methods. 2017 Jan;132:69-75. doi: 10.1016/j.mimet.2016.11.001. Epub 2016 Nov 9.

PMID:
27836633
14.

UN High-Level Meeting on antimicrobials--what do we need?

Laxminarayan R, Amábile-Cuevas CF, Cars O, Evans T, Heymann DL, Hoffman S, Holmes A, Mendelson M, Sridhar D, Woolhouse M, Røttingen JA.

Lancet. 2016 Jul 16;388(10041):218-20. doi: 10.1016/S0140-6736(16)31079-0. No abstract available.

PMID:
27479554
15.

Antimicrobial resistance-a threat to the world's sustainable development.

Jasovský D, Littmann J, Zorzet A, Cars O.

Ups J Med Sci. 2016 Aug;121(3):159-64. doi: 10.1080/03009734.2016.1195900. Epub 2016 Jul 14. Review.

16.

Repeated nationwide point-prevalence surveys of antimicrobial use in Swedish hospitals: data for actions 2003-2010.

Skoog G, Struwe J, Cars O, Hanberger H, Odenholt I, Prag M, Skärlund K, Ulleryd P, Erntell M.

Euro Surveill. 2016 Jun 23;21(25). doi: 10.2807/1560-7917.ES.2016.21.25.30264.

17.

Dynamic interaction of colistin and meropenem on a WT and a resistant strain of Pseudomonas aeruginosa as quantified in a PK/PD model.

Mohamed AF, Kristoffersson AN, Karvanen M, Nielsen EI, Cars O, Friberg LE.

J Antimicrob Chemother. 2016 May;71(5):1279-90. doi: 10.1093/jac/dkv488. Epub 2016 Feb 4.

PMID:
26850719
18.

Prevalence of hypermutators among clinical Acinetobacter baumannii isolates.

Komp Lindgren P, Higgins PG, Seifert H, Cars O.

J Antimicrob Chemother. 2016 Mar;71(3):661-5. doi: 10.1093/jac/dkv378. Epub 2015 Dec 9.

19.

A mechanism-based pharmacokinetic/pharmacodynamic model allows prediction of antibiotic killing from MIC values for WT and mutants.

Khan DD, Lagerbäck P, Cao S, Lustig U, Nielsen EI, Cars O, Hughes D, Andersson DI, Friberg LE.

J Antimicrob Chemother. 2015 Nov;70(11):3051-60. doi: 10.1093/jac/dkv233. Epub 2015 Sep 7.

PMID:
26349518
20.

Universal Access to Effective Antibiotics is Essential for Tackling Antibiotic Resistance.

Daulaire N, Bang A, Tomson G, Kalyango JN, Cars O.

J Law Med Ethics. 2015 Summer;43 Suppl 3:17-21. doi: 10.1111/jlme.12269.

PMID:
26243238
21.

Antibiotic resistance: An ethical challenge.

Littmann J, Buyx A, Cars O.

Int J Antimicrob Agents. 2015 Oct;46(4):359-61. doi: 10.1016/j.ijantimicag.2015.06.010. Epub 2015 Jul 20.

PMID:
26242553
22.

Changes in patterns of antibiotic use in Chinese public hospitals (2005-2012) and a benchmark comparison with Sweden in 2012.

Sun J, Shen X, Li M, He L, Guo S, Skoog G, Grape M, Cars O, Dong S.

J Glob Antimicrob Resist. 2015 Jun;3(2):95-102. doi: 10.1016/j.jgar.2015.03.001. Epub 2015 Apr 8.

PMID:
27873677
23.

In memoriam: William A. Craig.

Theuretzbacher U, Ambrose PG, MacGowan AP, Andes DR, Sörgel F, Derendorf H, Mouton JW, Drusano GL, Tulkens PM, Dudley MN, Cars O, Nation RL.

Antimicrob Agents Chemother. 2015;59(6):2971. doi: 10.1128/AAC.00849-15. Epub 2015 Apr 20. No abstract available.

24.

An international legal framework to address antimicrobial resistance.

Hoffman SJ, Outterson K, Røttingen JA, Cars O, Clift C, Rizvi Z, Rotberg F, Tomson G, Zorzet A.

Bull World Health Organ. 2015 Feb 1;93(2):66. doi: 10.2471/BLT.15.152710. No abstract available.

25.
26.

Pharmacodynamic studies of nitrofurantoin against common uropathogens.

Komp Lindgren P, Klockars O, Malmberg C, Cars O.

J Antimicrob Chemother. 2015 Apr;70(4):1076-82. doi: 10.1093/jac/dku494. Epub 2014 Dec 15.

PMID:
25515669
27.

Framework for optimisation of the clinical use of colistin and polymyxin B: the Prato polymyxin consensus.

Nation RL, Li J, Cars O, Couet W, Dudley MN, Kaye KS, Mouton JW, Paterson DL, Tam VH, Theuretzbacher U, Tsuji BT, Turnidge JD.

Lancet Infect Dis. 2015 Feb;15(2):225-34. doi: 10.1016/S1473-3099(14)70850-3. Epub 2014 Oct 21.

PMID:
25459221
28.

Antibiotic use worldwide.

Högberg LD, Muller A, Zorzet A, Monnet DL, Cars O.

Lancet Infect Dis. 2014 Dec;14(12):1179-80. doi: 10.1016/S1473-3099(14)70987-9. Epub 2014 Nov 17. No abstract available.

PMID:
25455983
29.

Antibiotic resistance--problems, progress, and prospects.

Nathan C, Cars O.

N Engl J Med. 2014 Nov 6;371(19):1761-3. doi: 10.1056/NEJMp1408040. Epub 2014 Oct 1. No abstract available.

30.

Mutant prevention concentrations of pradofloxacin for susceptible and mutant strains of Escherichia coli with reduced fluoroquinolone susceptibility.

Marcusson LL, Komp Lindgren P, Olofsson SK, Hughes D, Cars O.

Int J Antimicrob Agents. 2014 Oct;44(4):354-7. doi: 10.1016/j.ijantimicag.2014.06.010. Epub 2014 Jul 25.

PMID:
25129317
31.

Securing access to effective antibiotics for current and future generations. Whose responsibility?

Cars O.

Ups J Med Sci. 2014 May;119(2):209-14. doi: 10.3109/03009734.2014.912700. Epub 2014 Apr 27. No abstract available.

32.

Global survey of polymyxin use: A call for international guidelines.

Wertheim H, Van Nguyen K, Hara GL, Gelband H, Laxminarayan R, Mouton J, Cars O.

J Glob Antimicrob Resist. 2013 Sep;1(3):131-134.

33.

Access, excess, and ethics--towards a sustainable distribution model for antibiotics.

Heyman G, Cars O, Bejarano MT, Peterson S.

Ups J Med Sci. 2014 May;119(2):134-41. doi: 10.3109/03009734.2014.904958. Epub 2014 Apr 15. Review.

34.
35.

Evaluation of double- and triple-antibiotic combinations for VIM- and NDM-producing Klebsiella pneumoniae by in vitro time-kill experiments.

Tängdén T, Hickman RA, Forsberg P, Lagerbäck P, Giske CG, Cars O.

Antimicrob Agents Chemother. 2014;58(3):1757-62. doi: 10.1128/AAC.00741-13. Epub 2014 Jan 6.

36.

Antibiotic resistance-the need for global solutions.

Laxminarayan R, Duse A, Wattal C, Zaidi AK, Wertheim HF, Sumpradit N, Vlieghe E, Hara GL, Gould IM, Goossens H, Greko C, So AD, Bigdeli M, Tomson G, Woodhouse W, Ombaka E, Peralta AQ, Qamar FN, Mir F, Kariuki S, Bhutta ZA, Coates A, Bergstrom R, Wright GD, Brown ED, Cars O.

Lancet Infect Dis. 2013 Dec;13(12):1057-98. doi: 10.1016/S1473-3099(13)70318-9. Epub 2013 Nov 17. Erratum in: Lancet Infect Dis. 2014 Jan;14(1):11. Lancet Infect Dis. 2014 Mar;14(3):182.

PMID:
24252483
37.

Cell-wall-inhibiting antibiotic combinations with activity against multidrug-resistant Klebsiella pneumoniae and Escherichia coli.

Hickman RA, Hughes D, Cars T, Malmberg C, Cars O.

Clin Microbiol Infect. 2014 Apr;20(4):O267-73. doi: 10.1111/1469-0691.12374. Epub 2013 Oct 2.

38.

Consistent global approach on reporting of colistin doses to promote safe and effective use.

Nation RL, Li J, Cars O, Couet W, Dudley MN, Kaye KS, Mouton JW, Paterson DL, Tam VH, Theuretzbacher U, Tsuji BT, Turnidge JD.

Clin Infect Dis. 2014 Jan;58(1):139-41. doi: 10.1093/cid/cit680. Epub 2013 Oct 8. No abstract available.

PMID:
24107410
39.

Frequent emergence of porin-deficient subpopulations with reduced carbapenem susceptibility in ESBL-producing Escherichia coli during exposure to ertapenem in an in vitro pharmacokinetic model.

Tängdén T, Adler M, Cars O, Sandegren L, Löwdin E.

J Antimicrob Chemother. 2013 Jun;68(6):1319-26. doi: 10.1093/jac/dkt044. Epub 2013 Mar 10.

PMID:
23478794
40.

Colistin methanesulfonate and colistin pharmacokinetics in critically ill patients receiving continuous venovenous hemodiafiltration.

Karvanen M, Plachouras D, Friberg LE, Paramythiotou E, Papadomichelakis E, Karaiskos I, Tsangaris I, Armaganidis A, Cars O, Giamarellou H.

Antimicrob Agents Chemother. 2013 Jan;57(1):668-71. doi: 10.1128/AAC.00985-12. Epub 2012 Nov 12.

41.

Application of a loading dose of colistin methanesulfonate in critically ill patients: population pharmacokinetics, protein binding, and prediction of bacterial kill.

Mohamed AF, Karaiskos I, Plachouras D, Karvanen M, Pontikis K, Jansson B, Papadomichelakis E, Antoniadou A, Giamarellou H, Armaganidis A, Cars O, Friberg LE.

Antimicrob Agents Chemother. 2012 Aug;56(8):4241-9. doi: 10.1128/AAC.06426-11. Epub 2012 May 21.

42.

3Rs for innovating novel antibiotics: sharing resources, risks, and rewards.

So AD, Ruiz-Esparza Q, Gupta N, Cars O.

BMJ. 2012 Apr 3;344:e1782. doi: 10.1136/bmj.e1782. No abstract available.

PMID:
22491076
43.

[National recommendations for the treatment of pharyngotonsillitis are valid].

Cars O, Mölstad S, Norman C, Ternhag A, André M, Erntell M.

Lakartidningen. 2012 Jan 18-24;109(3):108-9. Swedish. No abstract available.

PMID:
22451987
44.

[Metronidazole cream approved for nonprescription use].

Edlund C, Rastad JA, Cars O, Erntell M.

Lakartidningen. 2011 Oct 5-11;108(40):1976. Swedish. No abstract available.

PMID:
22111242
45.

Pharmacokinetic-pharmacodynamic model for gentamicin and its adaptive resistance with predictions of dosing schedules in newborn infants.

Mohamed AF, Nielsen EI, Cars O, Friberg LE.

Antimicrob Agents Chemother. 2012 Jan;56(1):179-88. doi: 10.1128/AAC.00694-11. Epub 2011 Oct 28.

46.

Pharmacokinetic/pharmacodynamic (PK/PD) indices of antibiotics predicted by a semimechanistic PKPD model: a step toward model-based dose optimization.

Nielsen EI, Cars O, Friberg LE.

Antimicrob Agents Chemother. 2011 Oct;55(10):4619-30. doi: 10.1128/AAC.00182-11. Epub 2011 Aug 1.

47.

Protein binding: do we ever learn?

Zeitlinger MA, Derendorf H, Mouton JW, Cars O, Craig WA, Andes D, Theuretzbacher U.

Antimicrob Agents Chemother. 2011 Jul;55(7):3067-74. doi: 10.1128/AAC.01433-10. Epub 2011 May 2. Review.

48.

Posaconazole in human serum: a greater pharmacodynamic effect than predicted by the non-protein-bound serum concentration.

Lignell A, Löwdin E, Cars O, Chryssanthou E, Sjölin J.

Antimicrob Agents Chemother. 2011 Jul;55(7):3099-104. doi: 10.1128/AAC.01671-10. Epub 2011 Apr 18.

49.

The global need for effective antibiotics-moving towards concerted action.

Cars O, Hedin A, Heddini A.

Drug Resist Updat. 2011 Apr;14(2):68-9. doi: 10.1016/j.drup.2011.02.006. Epub 2011 Apr 1. Review.

PMID:
21444235
50.

Critical shortage of new antibiotics in development against multidrug-resistant bacteria-Time to react is now.

Freire-Moran L, Aronsson B, Manz C, Gyssens IC, So AD, Monnet DL, Cars O; ECDC-EMA Working Group.

Drug Resist Updat. 2011 Apr;14(2):118-24. doi: 10.1016/j.drup.2011.02.003. Epub 2011 Mar 23. Review.

PMID:
21435939

Supplemental Content

Support Center